Swedish developer of NIOX brand medical devices Aerocrine has entered into partnership with US-based Microsoft for its secure cloud services that will help transfer device telemetry data.
The device’s telemetry data will be transmitted from physician and company sites in Sweden, the UK and US back to Aerocrine for analysis.
The Swedish firm intends to use this information to deploy its field resources for customer service and sales support in the future.
Physicians use Aerocrine’s devices to measure fractional exhaled nitric oxide (FeNO), a biomarker for allergic, airway inflammation which is linked with asthma.
Aerocrine CEO Scott Myers said: "The ability to collect vital telemetry data from deployed devices has been a key objective of ours.
"A cloud-based solution allowing us to collect data on device performance in real-time helps us to be more proactive in our customer support and ensure that our NIOX devices help the physicians deliver the best possible outcome for the patient."
With the FeNO-testing device, physician can accurately identify the patients, the type of medication they should receive, as well as monitor the patients’ progress helping them to maintain adequate control and minimise exacerbations.
For this pilot project, proof-of-concept will be conducted in autumn this year, and the data will be collected from Aerocrine devices deployed in Sweden, the UK and US.
In the first phase, Microsoft will connect the Aerocrine devices to its secure cloud analytics platform, Microsoft Azure, to show the secure and accurate transmission of telemetry data.
Microsoft Sweden Industry Marketing development manager Mathias Ekman said: "We are excited to work with Aerocrine on this project as part of the CityNext, Healthier Cities initiative to show the potential of new technology to drive productivity and patient safety as we move towards a mobile-first and cloud-first world."
Image: Aerocrine’s NIOX MINO. Photo: courtesy of Aerocrine AB.